CODIE VASSAR: Open Payments
NPI 1538690995 · KENOSHA, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$478 in 24 payments from 10 companies in 2025. Trend: 2023 $81 · 2024 $845 · 2025 $478
Food & beverage: $478
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| ABBVIE INC. | 4 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
| Tris Pharma Inc | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Lundbeck LLC | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: REXULTI, INGREZZA, VRAYLAR, CAPLYTA, AUSTEDO XR, Dyanavel XR, Auvelity, INVEGA SUSTENNA.
Industry payments across WI — which companies pay providers there.
